Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196106 | 0.89 | APP (0.30) | — | |
| SCHEMBL2714181 | 0.86 | — | — | |
| SCHEMBL6113730 | 0.85 | — | — | |
| SCHEMBL6113845 | 0.85 | — | — | |
| SCHEMBL2712271 | 0.84 | — | — | |
| SCHEMBL2870636 | 0.82 | PTGS1 (0.31) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL2876581 | 0.82 | APP (0.38) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL2714268 | 0.81 | ATR (0.32) | — | |
| SCHEMBL2712406 | 0.78 | CYP4F2 (0.31) | — | |
| SCHEMBL6113871 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | claimed |
| JP-2012500209-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2312939-A1 | ANTIMICROBIAL GEL FORMULATIONS | NovaBay Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | claimed |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | claimed |
| WO-2010019723-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227201-A1 | Antimicrobial Gel Formulations | CUTA, TUBA3C, POLR1C | PTGS1 1663/4885PDE4A 3701/4885LMNA 3899/4885 |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | CUTA, TUBA3C, POLR1C | PTGS1 1663/4885PDE4A 3701/4885LMNA 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.